Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019
| Title: | Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019 |
|---|---|
| Authors: | Nicole Balmaceda, Muhammad Aziz, Viveksandeep Thoguluva Chandrasekar, Brian McClune, Suman Kambhampati, Leyla Shune, Al-Ola Abdallah, Faiz Anwer, Aneela Majeed, Muzaffar Qazilbash, Siddhartha Ganguly, Joseph McGuirk, Ghulam Rehman Mohyuddin |
| Source: | BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021) |
| Publisher Information: | BMC, 2021. |
| Publication Year: | 2021 |
| Collection: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| Subject Terms: | Multiple myeloma, Proteasome inhibitors, Anti-CD38, Cytotoxic therapy, Infection, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| More Details: | Abstract Background Patients with multiple myeloma (MM) remain at an increased risk of infection due to the disease process, as well as the ensuing treatments. Methods We performed a systematic review to evaluate the monthly risk of grade III/IV infection, pneumonia, and neutropenia in patients with myeloma enrolled in randomized clinical trials (RCTs). Results The risk of grade III or higher infection, pneumonia, and neutropenia persists among all phases of treatment. There was no statistical difference in grade III or higher infection, pneumonia, and neutropenia between frontline and relapsed/refractory setting. In the maintenance setting, the complications of infection, pneumonia, and neutropenia were low, but not negligible. Three-drug regimens were no more likely than two-drug regimens to have an increased risk of Grade III or higher infection. Conclusions This is the first study to quantify the monthly risk of grade III or higher infection, pneumonia, and neutropenia across different treatment regimens in the frontline, maintenance, and relapsed/refractory settings. The results of our systematic review demonstrate a significant risk for severe infection, pneumonia, and neutropenia in patients with MM. Further studies are needed to determine the value of antibiotic prophylaxis in a broader myeloma patient population, as well as other approaches that will further mitigate the morbidity and mortality related to infection in this vulnerable patient population. |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 1471-2407 99557738 |
| Relation: | https://doaj.org/toc/1471-2407 |
| DOI: | 10.1186/s12885-021-08451-x |
| Access URL: | https://doaj.org/article/cb3bb2d95ce64ff995577383bb9c055e |
| Accession Number: | edsdoj.b3bb2d95ce64ff995577383bb9c055e |
| Database: | Directory of Open Access Journals |
| ISSN: | 14712407 99557738 |
|---|---|
| DOI: | 10.1186/s12885-021-08451-x |
| Published in: | BMC Cancer |
| Language: | English |